Research Paper Volume 13, Issue 22 pp 24580—24604

BMPR2 promoter methylation and its expression in valvular heart disease complicated with pulmonary artery hypertension

The DNA methylation level at the second CpG site (Pos. 2) of the BMPR2 promoter was affected by the VHD clinicopathological factors. (A) The DNA methylation levels at Pos. 2 of BMPR2 were more significantly increased in the male patients than the females in comparison to the controls. (B) The DNA methylation levels at Pos. 2 of BMPR2 were shown in different age groups of VHD patients. (C) The DNA methylation levels at Pos. 2 of BMPR2 were more significantly increased in the VHD patients with more severe PAH than those with mild PAH. Moderate/severe PAH, PASP≥55mmHg. Mild PAH, 30 mmHg ≤ PASP D) The operation type of MVR or AVR or DVR had no effect on the BMPR2 promoter DNA methylation levels at Pos. 2 of BMPR2. MVR, mitral valve replacement; AVR, aortic valve replacement. DVR, double valve replacement. For statistical comparisons, *P **P

Figure 2. The DNA methylation level at the second CpG site (Pos. 2) of the BMPR2 promoter was affected by the VHD clinicopathological factors. (A) The DNA methylation levels at Pos. 2 of BMPR2 were more significantly increased in the male patients than the females in comparison to the controls. (B) The DNA methylation levels at Pos. 2 of BMPR2 were shown in different age groups of VHD patients. (C) The DNA methylation levels at Pos. 2 of BMPR2 were more significantly increased in the VHD patients with more severe PAH than those with mild PAH. Moderate/severe PAH, PASP≥55mmHg. Mild PAH, 30 mmHg ≤ PASP < 55 mmHg. (D) The operation type of MVR or AVR or DVR had no effect on the BMPR2 promoter DNA methylation levels at Pos. 2 of BMPR2. MVR, mitral valve replacement; AVR, aortic valve replacement. DVR, double valve replacement. For statistical comparisons, *P < 0.05. **P < 0.01.